Search results for " pharmacy."

showing 10 items of 356 documents

In vivo measurement of gastric fluid volume in anesthetized dogs

2020

Abstract The drug solubility is critical for the Biopharmaceutics Classification System (BCS), yet the criteria for solubility have not been precisely defined for dogs. In particular, the gastric fluid volume (GFV) of dogs which is used to measure the solubility has not been quantified in vivo. The aim of the work is to measure the GFV using magnetic resonance imaging (MRI) from 12 Beagle dogs weighing 9–12 kg (6 male and 6 female). We found that the average GFV within this weight range was 24.0 ± 4.2 mL. The result can be used for the BCS studies of canine drugs and also serves as a reference for other species.

Gastric fluidmedicine.diagnostic_testbusiness.industryPharmaceutical ScienceMagnetic resonance imaging02 engineering and technology021001 nanoscience & nanotechnologyWeight rangeBiopharmaceutics Classification System030226 pharmacology & pharmacyBeagle03 medical and health sciences0302 clinical medicineVolume (thermodynamics)In vivoMedicineSolubility0210 nano-technologybusinessBiomedical engineeringJournal of Drug Delivery Science and Technology
researchProduct

Mangiferin glycethosomes as a new potential adjuvant for the treatment of psoriasis

2020

[EN] Mangiferin, a natural compound isolated from Mangifera indica L, was incorporated in glycerosomes, ethosomes and alternatively in glycerol-ethanol phospholipid vesicles (glycethosomes). Actually, only glycethosomes were able to stably incorporate the mangiferin that was loaded at increasing concentrations (2, 4, 6, 8 mg/mL). The morphology, size distribution, rheological properties, surface charge and entrapment efficiency of prepared vesicles were deeply measured. All vesicles were mainly spherical, oligolamellar, small in size (similar to 145 nm) and negatively charged (similar to-40 mV), as confirmed by cryo-TEM observation and dynamic laser light scattering measurements. The higher…

GlycerolAntioxidantDrug CompoundingXanthonesmedicine.medical_treatmentPharmaceutical Science02 engineering and technologyAdministration Cutaneous030226 pharmacology & pharmacyMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivoPhospholipid vesiclesGlycerolmedicineAnimalsHumansPsoriasisTissue DistributionMangiferinHydrogen peroxidePhospholipidsSkin permeationAdjuvants PharmaceuticDrug CarriersWound HealingMangiferaEthanolVesicle3T3 CellsHydrogen Peroxide021001 nanoscience & nanotechnologyIn vitroDisease Models AnimalchemistryBiophysicsMangiferinGlycethosomesTetradecanoylphorbol AcetateFemaleAntioxidantEpidermis0210 nano-technologyDrug carrierInternational Journal of Pharmaceutics
researchProduct

Inhalable polymer-glycerosomes as safe and effective carriers for rifampicin delivery to the lungs

2016

Rifampicin loaded glycerosomes, vesicles composed of phospholipids, glycerol and water, were combined with trimethyl chitosan chloride (TMC) to prepare TMC-glycerosomes or, alternatively, with sodium hyaluronate (HY) to obtain HY-glycerosomes. These new hybrid nanovesicles were tested as carriers for pulmonary delivery of rifampicin. Glycerosomes without polymers were also prepared and characterized. All vesicles were similar: they were spherical, multilamellar and able to incorporate good amount of rifampicin (EE%∼55%). The addition of the polymers to the formulations allowed an increase of mean diameter. All the glycerosomes, in particular HY-glycerosomes, were able to deliver the drug to…

GlycerolMaleDrugStaphylococcus aureusCell SurvivalPolymersmedia_common.quotation_subjectSodium hyaluronateMicrobial Sensitivity Tests02 engineering and technologyPharmacology030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineColloid and Surface ChemistryMicroscopy Electron TransmissionIn vivoAdministration InhalationGlycerolmedicineAnimalsHumansTissue DistributionRats WistarPhysical and Theoretical ChemistryAntibiotics AntitubercularLungmedia_commonDrug CarriersLiposomeVesicleSurfaces and InterfacesGeneral Medicine021001 nanoscience & nanotechnologychemistryA549 CellsLiposomesNanoparticlesRifampin0210 nano-technologyDrug carrierRifampicinBiotechnologymedicine.drugColloids and Surfaces B: Biointerfaces
researchProduct

Control de calidad en la fabricación y adaptación de productos ortoprotésicos a medida

2008

Health Sciences PharmacyUNESCO::QUÍMICA:QUÍMICA [UNESCO]
researchProduct

Estudios químico-analíticos para la determinación de Biguanidas en preparados farmacéuticos

1985

Health Sciences PharmacyUNESCO::QUÍMICA:QUÍMICA [UNESCO]
researchProduct

Aportaciones al estudio de la farmacología de acamprosato

2008

Health Sciences PharmacyUNESCO::QUÍMICAHealth Sciences Pharmacology:QUÍMICA [UNESCO]
researchProduct

Molecular docking and oxidation kinetics of 3-phenyl coumarin derivatives by human CYP2A13.

2021

CYP2A13 enzyme is expressed in human extrahepatic tissues, while CYP2A6 is a hepatic enzyme. Reactions catalysed by CYP2A13 activate tobacco-specific nitrosamines and some other toxic xenobiotics in lungs.To compare oxidation characteristics and substrate-enzyme active site interactions in CYP2A13 vs CYP2A6, we evaluated CYP2A13 mediated oxidation characteristics of 23 coumarin derivatives and modelled their interactions at the enzyme active site.CYP2A13 did not oxidise six coumarin derivatives to corresponding fluorescent 7-hydroxycoumarins. The Km-values of the other coumarins varied 0.85-97 µM, Vmax-values of the oxidation reaction varied 0.25-60 min-1, and intrinsic clearance varied 26-…

Health Toxicology and MutagenesisKineticsToxicology030226 pharmacology & pharmacyBiochemistryRedoxMedicinal chemistryCytochrome P-450 CYP2A603 medical and health scienceschemistry.chemical_compound0302 clinical medicineCytochrome P-450 Enzyme SystemCoumarinsHumansheterocyclic compoundsEnzyme kineticsCYP2A6Pharmacologychemistry.chemical_classificationbiologyChemistryActive siteGeneral MedicineCoumarinMolecular Docking SimulationKineticsEnzymeDocking (molecular)030220 oncology & carcinogenesisbiology.proteinAryl Hydrocarbon HydroxylasesXenobiotica; the fate of foreign compounds in biological systems
researchProduct

In vitro sulfonation of 7-hydroxycoumarin derivatives in liver cytosol of human and six animal species

2020

Sulfonation is an important high affinity elimination pathway for phenolic compounds.In this study sulfonation of 7-hydroxycoumarin and 13 its derivatives were evaluated in liver cytosols of human and six animal species. 7-hydroxycoumarin and its derivatives are strongly fluorescent, and their sulfate conjugates are nonfluorescent at excitation 405 nm and emission 460 nm. A convenient fluorescence based kinetic assay of sulfonation was established.The sulfonation rate of most of the 7-hydroxycoumarin derivatives was low in liver cytosol of human and pig, whereas it was high with most compounds in dog and intermediate in rat, mouse, rabbit, and sheep. Sulfonation of the 7-hydroxycoumarin der…

Health Toxicology and MutagenesisLiver cytosolToxicologyliver030226 pharmacology & pharmacyBiochemistryArticle03 medical and health sciences0302 clinical medicineanimalhumanAnimal specieskumariinitsulfonationPharmacologyChemistrymaksaGeneral MedicinelääkeaineetIn vitroBiochemistry7-hydroxycoumarinfarmakokinetiikka030220 oncology & carcinogenesiseläimetihmiset
researchProduct

The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A

2019

Abstract Background and objective Factor VIII (FVIII) is indicated for the prevention or treatment of bleeding in patients with hemophilia A. FVIII product stability under high and fluctuating temperatures is important, particularly for patients who reside in, or travel to, regions with high ambient temperatures, as they may remove their product from the refrigerator and return it, unused, multiple times. We evaluated the effect of variable temperature storage conditions, including up to 40 °C, on the stability of the recombinant FVIII product, turoctocog alfa. Methods Turoctocog alfa dry powder stability was assessed when moved between storage conditions of 5 °C (ambient humidity) and 40 °…

Hot TemperatureTime FactorsDrug StoragePharmacology toxicologyHemophilia A030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineAnimal scienceDrug StabilityAmbient humidityHumansPotencyRelative humidityIn patientOriginal Research Article030203 arthritis & rheumatologyPharmacologyFactor VIIIChemistrylcsh:RM1-950Turoctocog alfaCoagulation Factor VIII Room TemperatureStability Turoctocog-alfaRecombinant ProteinsCold TemperatureMolecular Weightlcsh:Therapeutics. PharmacologyDry powderOxidation-ReductionDrugs in R&D
researchProduct

Nanoparticle formulations as recrystallization inhibitors in transdermal patches

2020

Abstract Drug crystallization in transdermal patches is still a major challenge, confronting the formulation development of topical drug delivery systems. Encapsulation of drugs into nanoparticles is proposed here as a promising tool for regulating drug crystallization in transdermal patches. The degree of recrystallization and transdermal permeation of ibuprofen and hydrocortisone loaded in polymeric and lipid nanoparticles from matrix-type transdermal patches were investigated. Ethyl cellulose (EC4), poly (lactide-co-glycolic acid) (PLGA) and polycaprolactone (PCL) were employed for polymeric nanoparticle preparations; while medium chain triglyceride (MCT) and witepsol were used for the p…

HydrocortisoneSwinePolyestersSkin AbsorptionTransdermal PatchPharmaceutical ScienceNanoparticleIbuprofen02 engineering and technology030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePolylactic Acid-Polyglycolic Acid CopolymerEthyl celluloseSolid lipid nanoparticlemedicineAnimalsCelluloseTriglyceridesSkinTransdermalDrug CarriersChemistry021001 nanoscience & nanotechnologyIbuprofenDrug LiberationPLGAChemical engineeringPolycaprolactoneNanoparticlesNanocarriersCrystallization0210 nano-technologymedicine.drugInternational Journal of Pharmaceutics
researchProduct